Press Releases Year None2024202320222021 March 12, 2024 NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD February 28, 2024 NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update February 26, 2024 NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March February 13, 2024 NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants February 13, 2024 NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants February 1, 2024 NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference January 8, 2024 NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors January 4, 2024 NewAmsterdam Pharma Announces 2024 Strategic Priorities Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4 Displaying 31 - 38 of 38
March 12, 2024 NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD
February 28, 2024 NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update
February 13, 2024 NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
February 13, 2024 NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
February 1, 2024 NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
January 8, 2024 NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors
